Terms: = Brain cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Clinical Outcome
4 results:
1. MYCN amplification drives an aggressive form of spinal ependymoma.
Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
[TBL] [Abstract] [Full Text] [Related]
2. New therapeutic options for advanced non-resectable malignant melanoma.
Stadler S; Weina K; Gebhardt C; Utikal J
Adv Med Sci; 2015 Mar; 60(1):83-8. PubMed ID: 25596540
[TBL] [Abstract] [Full Text] [Related]
3. Cystic papillary meningioma with subarachnoid dissemination: a case report and review of the literature.
Zhi L; Bing L; Yang L; Bo-ning L; Quan H
Pathol Res Pract; 2009; 205(8):582-7. PubMed ID: 19307065
[TBL] [Abstract] [Full Text] [Related]
4. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
[TBL] [Abstract] [Full Text] [Related]
